POPULATION PHARMACOKINETICS OF AMIKACIN IN INTENSIVE-CARE UNIT PATIENTS STUDIED BY NPEM ALGORITHM

被引:16
|
作者
DEBORD, J
PESSIS, C
VOULTOURY, JC
MARQUET, P
LOTFI, H
MERLE, L
LACHSATRE, G
机构
[1] HOP DUPUYTREN,SERV PHARMACOL TOXICOL,F-87042 LIMOGES,FRANCE
[2] HOP DUPUYTREN,SERV REANIMAT POLYVALENTE,F-87042 LIMOGES,FRANCE
[3] FAC PHARM LIMOGES,TOXICOL LAB,F-87025 LIMOGES,FRANCE
关键词
AMIKACIN; POPULATION PHARMACOKINETICS; NPEM ALGORITHM; BAYESIAN ESTIMATION; PREDICTIVE PERFORMANCE;
D O I
10.1111/j.1472-8206.1995.tb00266.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The population pharmacokinetics of amikacin was studied in 40 intensive care unit patients (212 plasma concentrations) by NPEM algorithm using a one-compartment model. The population was best characterized by the following pharmacokinetic parameters: renal clearance relative to creatinine clearance (C-s = 0.96 +/- 0.33), and either the total volume of distribution (V-d = 23.9 +/- 7.01) or the volume of distribution relative to body weight (V-s = 0.36 +/- 0.10 l.kg(-1). The volume of distribution was increased with respect to the usual value of 0.25 l.kg(-1). The statistical distribution of these pharmacokinetic parameters was approximately gaussian, with no significant correlation between volume of distribution and clearance. The medians and standard deviations of C-s and V-s were used as reference population values to estimate the pharmacokinetics of amikacin in a second group of 29 patients by the bayesian method, with two blood samples per patient. For each patient, the fitted parameters were able to predict the plasma concentrations of amikacin during the next 72 h with no significant bias and good precision (2.9 mg.l(-1) for peaks and 0.5 mg.l(-1) for troughs). This study confirms the ability of the NPEM algorithm to provide reference population values for use in bayesian monitoring of aminoglycoside therapy.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 50 条
  • [21] DOBUTAMINE PHARMACOKINETICS IN PEDIATRIC INTENSIVE-CARE PATIENTS
    HABIB, DM
    PADBURY, JF
    PERKIN, RM
    ANAS, NG
    MARTINEZ, AM
    MINAGAR, C
    CLINICAL RESEARCH, 1989, 37 (01): : A176 - A176
  • [22] 5 YEARS OF EXPERIENCE WITH THE EXCLUSIVE USE OF AMIKACIN IN A NEONATAL INTENSIVE-CARE UNIT
    POWELL, KR
    PINCUS, PH
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1987, 6 (05) : 461 - 466
  • [23] AN INTENSIVE-CARE UNIT
    WOOLEVER, GM
    NURSING OUTLOOK, 1958, 6 (12) : 690 - 691
  • [24] INTENSIVE-CARE UNIT
    FREYBERGER, H
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 1975, 26 (06) : 337 - 343
  • [25] POPULATION PHARMACOKINETICS - DEVELOPMENT OF A MEDICAL INTENSIVE-CARE UNIT-SPECIFIC GENTAMICIN DOSING NOMOGRAM
    WATLING, SM
    KISOR, DF
    ANNALS OF PHARMACOTHERAPY, 1993, 27 (02) : 151 - 154
  • [26] Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit
    Rajagopalan, P
    Pelz, RK
    Lipsett, PA
    Swoboda, SM
    Rinaldi, MG
    Hendrix, CW
    PHARMACOTHERAPY, 2003, 23 (05): : 592 - 602
  • [27] GENTAMICIN-(G) PHARMACOKINETICS (PK) IN PEDIATRIC INTENSIVE-CARE UNIT (PICU) PATIENTS
    KRAUS, DM
    DUSIK, CM
    KECSKES, SA
    RODVOLD, KA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 144 - 144
  • [28] THORACIC SURGICAL PATIENTS IN INTENSIVE-CARE UNIT
    MERIKALLIO, EM
    VILKKO, PS
    TALA, P
    ANNALES CHIRURGIAE ET GYNAECOLOGIAE, 1974, 63 (04) : 265 - 270
  • [29] TECHNIQUES OF TRACHEOSTOMY FOR INTENSIVE-CARE UNIT PATIENTS
    PRICE, DG
    ANAESTHESIA, 1983, 38 (09) : 902 - 904
  • [30] NUTRITIONAL ASSESSMENT OF INTENSIVE-CARE UNIT PATIENTS
    MURRAY, MJ
    MARSH, HM
    WOCHOS, DN
    MOXNESS, KE
    OFFORD, KP
    CALLAWAY, CW
    MAYO CLINIC PROCEEDINGS, 1988, 63 (11) : 1106 - 1115